

1 **Global longitudinal strain and plasma biomarkers for prognosis in heart failure**
2 **complicated by diabetes.**

3
4 Nithin R. Iyer MD^{1,2}, Siew-Pang Chan PhD³, Oi Wah Liew⁴, Jenny P.C. Chong⁴, Jennifer A.
5 Bryant PhD¹, Thu-Thao Le PhD^{1,5}, Chanchal Chandramouli PhD^{6,7}, Patrick J. Cozzone PhD⁸,
6 Frank Eisenhaber MD PhD^{9,10,11}, Roger Foo MD^{4,10}, A. Mark Richards MD PhD^{4,12}, Carolyn
7 S.P. Lam MD PhD^{1,6,7,13}, Martin Ugander§ MD PhD^{2,14}, Calvin W-L. Chin§ MD PhD^{5,6} and
8 on behalf of the ATTRaCT investigators
9

10 ¹National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore

11 ²Kolling Institute, Royal North Shore Hospital, and University of Sydney, Australia

12 ³Yong Loo Lin School of Medicine, National University of Singapore, Singapore

13 ⁴Cardiovascular Research Institute, Yong Loo Lin School of Medicine, National University
14 of Singapore, Singapore

15 ⁵Cardiovascular Sciences ACP, Duke NUS Medical School, Singapore

16 ⁶National Heart Centre Singapore, Singapore

17 ⁷Duke-National University Singapore, Singapore

18 ⁸Singapore Bioimaging Consortium, Agency for Science, Technology and Research,
19 Singapore

20 ⁹Bioinformatics Institute, Agency for Science, Technology and Research, Singapore

21 ¹⁰Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore

22 ¹¹School of Biological Sciences, Nanyang Technological University, Singapore

23 ¹²Christchurch Heart Institute, University of Otago, Christchurch, New Zealand

24 ¹³University Medical Centre Groningen, Groningen, The Netherlands

25 ¹⁴Department of Clinical Physiology, Karolinska University Hospital, and Karolinska
26 Institutet, Stockholm, Sweden

27 § denotes equal contribution
28
29

30 **Address for Correspondence**

31
32 Calvin W-L. Chin, MD PhD

33 Department of Cardiology, National Heart Centre Singapore, 5 Hospital Drive Singapore
34 169609

35 E: calvin.chin.w.l@singhealth.com.sg

36 T: +65 67048962
37
38

39

40

41

42 **Abstract**

43 **Background:** Heart failure (HF) and diabetes are associated with increased incidence and
44 worse prognosis of each other. The prognostic value of global longitudinal strain (GLS)
45 measured by cardiovascular magnetic resonance (CMR) has not been established in HF
46 patients with diabetes.

47 **Methods:** Consecutive patients (n=315) with HF underwent CMR at 3T, including GLS, late
48 gadolinium enhancement (LGE), native T1, and extracellular volume fraction (ECV)
49 mapping. Plasma biomarker concentrations were measured including: N-terminal pro B-type
50 natriuretic peptide(NT-proBNP), high-sensitivity troponin T(hs-TnT), growth differentiation
51 factor 15(GDF-15), soluble ST2(sST2) and galectin 3(Gal-3). The primary outcome was a
52 composite of all-cause mortality or HF hospitalisation.

53 **Results:** Compared to those without diabetes (n=156), the diabetes group (n=159) had a
54 higher LGE prevalence (76 vs 60%, p<0.05), higher T1 (1285±42 vs 1269±42ms, p<0.001)
55 and higher ECV (30.5±3.5 vs 28.8±4.1%, p<0.001). The diabetes group had higher NT-pro-
56 BNP, hs-TnT, GDF-15, sST2 and Gal-3. Diabetes conferred worse prognosis (hazard ratio
57 (HR) 2.33 [95% confidence interval (CI) 1.43-3.79], p<0.001). In multivariable Cox
58 regression analysis including clinical markers and plasma biomarkers, sST2 alone remained
59 independently associated with the primary outcome (HR per 1 ng/mL 1.04 [95% CI 1.02-
60 1.07], p=0.001). In multivariable Cox regression models in the diabetes group, both GLS and
61 sST2 remained prognostic (GLS: HR 1.12 [95% CI 1.03-1.21], p=0.01; sST2: HR per 1
62 ng/mL 1.03 [95% CI 1.00-1.06], p=0.02).

63 **Conclusions:** Compared to HF patients without diabetes, those with diabetes have worse
64 plasma and CMR markers of fibrosis and a more adverse prognosis. GLS is a powerful and
65 independent prognostic marker in HF patients with diabetes.

66

67 **Keywords**

68 magnetic resonance imaging, heart failure, global longitudinal strain, biomarkers, prognosis

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90 **Background**

91 The Asian continent has the highest prevalence of heart failure (HF) cases globally [1].

92 Diabetes is especially common in South East Asian HF populations, where a unique ‘lean-
93 diabetic’ phenotype with worse outcomes has been identified [2]. The Asian Sudden Cardiac
94 Death in Heart Failure (ASIAN-HF) registry (across 11 Asian countries) reported a 42.5%
95 prevalence of diabetes among HF patients, specifically in higher-income countries such as
96 Singapore, Hong Kong, and Thailand [3].

97

98 The diabetic heart is characterised by a number of structural abnormalities including diffuse
99 interstitial myocardial fibrosis, myocyte hypertrophy, and impaired coronary microvascular
100 perfusion, which have all been implicated in the development of both diastolic and systolic
101 dysfunction [4, 5]. Patients with HF and diabetes have consistently worse clinical outcomes,
102 including higher risk of hospitalisation for HF and death, compared to those without diabetes
103 [6-8]. These findings appear to hold regardless of whether the HF is ischaemic or non-
104 ischaemic in etiology, and regardless of left ventricular (LV) ejection fraction [7, 8].

105

106 Cardiac magnetic resonance (CMR) imaging has become the non-invasive reference standard
107 for evaluating HF due to its ability to accurately assess cardiac morphology, function, and
108 myocardial tissue characteristics. In particular, late gadolinium enhancement (LGE) permits
109 visualisation of focal replacement myocardial fibrosis, while T1 mapping pre- and post-
110 gadolinium contrast enables non-invasive measurement of the myocardial extracellular
111 volume fraction (ECV), a quantitative marker of myocardial diffuse interstitial fibrosis.
112 Additionally, global longitudinal strain (GLS), defined as the change in the LV myocardial
113 length between diastole and systole divided by the original end-diastolic length, provides a

114 measure of LV systolic function by CMR that is effectively the same as GLS measured by
115 echocardiography [9, 10].

116

117 Patients with diabetes frequently have impaired GLS and have a higher degree of myocardial
118 fibrosis as assessed by ECV and histology [11, 12]. GLS by CMR appears to have prognostic
119 value in HF regardless of ejection fraction and whether the cause of HF is ischemic or non-
120 ischemic [13-15]. There is a growing body of literature demonstrating the prognostic value of
121 GLS in asymptomatic patients with diabetes [16, 17]. However, the prognostic utility of GLS
122 in diabetes patients with established HF failure is unknown.

123

124 Growth differentiation factor-15 (GDF-15), soluble ST2 (sST2) and galectin 3 (Gal-3) are
125 circulating plasma biomarkers associated with inflammation, fibrosis and cardiac remodelling
126 [18]. Plasma concentrations of these biomarkers appear to provide prognostic information in
127 HF patients beyond established markers including cardiac troponins and natriuretic peptides
128 [18-21]. The prognostic relevance of these biomarkers has not yet been established in HF
129 patients with diabetes.

130

131 This study aimed to assess the prognostic significance of GLS by CMR and novel HF plasma
132 biomarkers associated with inflammation and fibrosis in a cohort of patients with HF and
133 diabetes across the spectrum of LV ejection fraction. We hypothesized that GLS would have
134 an incremental prognostic association in this group, beyond plasma HF biomarkers, LV
135 ejection fraction and CMR markers of myocardial fibrosis.

136

137 **Methods**

138 *Study Population*

139 Patients with HF were recruited prospectively across six tertiary cardiac centres in Singapore
140 (Asian neTwork for Translational Research and Cardiovascular Trials [ATTRaCT],
141 ClinicalTrials.gov NCT02791009). Patients were included if they presented to hospital with a
142 primary diagnosis of HF, or if they attended a hospital clinic within 6 months of an episode of
143 decompensated HF (requiring hospitalization or treatment in an out-patient setting). In all
144 cases, a trained cardiologist adjudicated the clinical diagnosis of HF. The exclusion criteria
145 were: HF primarily due to severe valve disease, HF due to acute coronary syndrome resulting
146 in a transient episode of acute pulmonary oedema, severe renal failure (estimated glomerular
147 filtration rate $< 15 \text{ mL/min per } 1.73\text{m}^2$), specific causes of HF (constrictive pericarditis,
148 complex adult congenital heart disease, hypertrophic cardiomyopathy, eosinophilic
149 myocarditis, cardiac amyloidosis, and acute chemotherapy-induced cardiomyopathy), isolated
150 right HF, and life threatening non-cardiac co-morbidity with life expectancy of < 1 year. All
151 patients underwent clinical assessment at baseline. Diabetes status was identified by baseline
152 questionnaire at recruitment.

153

154 *Biomarkers*

155 Blood was collected in dipotassium (K_2)-EDTA vacutainer tubes and transported on ice for
156 processing within one hour. Plasma was separated by centrifugation at 3500g for 10 minutes
157 at 4°C and stored at -80°C until analysis.

158

159 Plasma N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin
160 T (hs-TnT) were measured by electrochemiluminescence immunoassay using the Elecsys
161 proBNP G2 V2.1 and Elecsys Troponin T hs V2.1 assays on the Cobas e411 immuno-
162 analyser (Roche Diagnostic GmbH, Mannheim, Germany). The measurement ranges of NT-
163 proBNP and hs-TnT were 10-35000 pg/ml and 3-10000 pg/ml, respectively. Laboratory

164 average concentration and inter-assay coefficient of variation (%CV) of low (NT-proBNP:
165 147 pg/ml, 4.48%; hs-TnT: 26.8 pg/ml, 5.05%) and high (NT-proBNP: 4679 pg/ml, 4.97%;
166 hs-TnT: 2120 pg/ml, 3.69%) quality control samples of the NT-proBNP and hs-TnT assays
167 were established over 84 and 73 independent assays, respectively.

168

169 Human GDF-15 (R&D Systems, Minneapolis, MN, USA; Cat#DGD150), sST2 (Presage ST2
170 assay, Critical Diagnostics, California, USA) and Gal-3 (R&D Systems, Minneapolis, MN,
171 USA; Cat#DGAL30) were measured by ELISA on the Enspire Multimode Microplate Reader
172 (Perkin Elmer, Waltham, MA, USA). Results were interpolated from standard curves fitted
173 on 5-parameter logistic model (5-PL) using the instrument's Enspire® software. Laboratory
174 inter-assay %CV of quality control samples were 7.41% at 126 pg/ml, 7.71 % at 360 pg/ml
175 and 8.43% at 778 pg/ml for GDF-15 (n=98), 18.0% at 30.0 ng/ml and 15.2% at 63.6 ng/ml
176 for sST2 (n=98) and 10.4% at 0.83 ng/ml, 10.6% at 2.41 ng/ml and 12.3% at 4.82 ng/ml for
177 Galectin-3 (n=56).

178

179 *Clinical Outcomes*

180 The primary outcome was a composite of time to either first hospitalization for HF
181 (regardless of prior history of hospitalization for HF) or all-cause mortality. Follow-up was
182 conducted through a clinic visit at 6 months after baseline assessment and structured phone
183 interviews with the participants at the 1- and 2-year timepoints. Data in patients who were
184 lost to follow-up were censored at the date when the patient was last known to be alive and
185 had not experienced an event.

186

187 *Cardiovascular magnetic resonance image acquisition*

188 All patients in the ATTRaCT cohort were invited and assessed for suitability for CMR. Those

189 who agreed and were eligible underwent a standardized CMR protocol with a 3 Tesla MRI
190 scanner (Ingenia, Philips Healthcare, Best, The Netherlands). Balanced steady-state free
191 precision cines were acquired in the standard long-axis views and a short-axis stack from
192 base to apex, as described previously [22]. LGE images were acquired at 10 min after 0.1
193 mmol/kg of gadobutrol (Gadovist®, Bayer Pharma AG, Germany) with a phase sensitive
194 inversion-recovery gradient-echo imaging sequence. Typical parameters were: repetition time
195 (TR) = 6.1 ms; echo time (TE) = 3 ms; time to inversion (TI) = 320–340 ms, flip angle 25°,
196 voxel size = 1.5x1.7x8 mm, SENSE factor = 2.4, slice thickness 8mm with 2mm gap to
197 match short-axis cine slice positions. The inversion time for optimal myocardial nulling was
198 selected from an inversion time scout sequence. T1 maps were acquired at the basal and mid-
199 ventricular short-axis levels, pre- and 15-min post-contrast with modified Look-Locker
200 Inversion-recovery (MOLLI) 5s(3s)3s and 4s(1s)3s(1s)2s acquisition schemes, respectively
201 [23].

202

203 *CMR analysis*

204 Image analysis was performed using CVI42 software (Circle Cardiovascular Imaging,
205 Calgary, Canada) by trained imaging fellows at the National Heart Research Institute of
206 Singapore CMR Core Laboratory, who were blinded to the clinical information of the
207 patients. Ventricular volumes, mass and ejection fraction were measured from the short-axis
208 cine stack, using manual contouring of the left ventricle in end-diastole and end-systole,
209 excluding papillary muscles, as detailed previously [22]. LV volumes and mass data were
210 indexed to body surface area. The presence of LGE was assessed qualitatively by two readers
211 according to the recommendations by the Society of CMR [24]. Average native and post-
212 contrast myocardial T1 values were measured by placing a region of interest (ROI) within the
213 middle third of the short-axis myocardial wall at the basal- and mid-ventricular levels, while

214 avoiding regions of focal LGE. The myocardium-blood pool interface was carefully avoided
215 in order to prevent partial volume effects. Pre- and post-contrast blood T1 values were
216 measured in a ROI drawn within the blood pool. ECV was calculated from the pre- and post-
217 contrast average blood and myocardial T1 values, as described previously [25, 26].

218 Myocardial strain was analysed in the cine images using the Tissue Tracking Plugin [27].

219

220 *Statistics*

221 Normality was assessed for continuous variables using the Shapiro-Wilk test. Normally
222 distributed data are presented as mean \pm standard deviation. Non-normally distributed data
223 are presented as median [interquartile range]. Comparisons were performed for continuous
224 variables using the parametric Student *t*-test or the non-parametric Mann-Whitney U test.

225 Categorical variables are presented as number (percentage) and compared using the χ^2 test.

226

227 Univariable Cox regression analysis was performed to identify prognostic variables in the
228 entire cohort and also in the diabetes subgroup. Clinically relevant variables (age, sex, body
229 mass index, diabetes, smoking, coronary artery disease, hypertension, New York Heart
230 Association functional class and systolic blood pressure), circulating biomarkers (NT-
231 proBNP, hs-TnT, GDF-15, sST2 and Gal-3) and CMR markers of function, remodelling and
232 fibrosis (LV end diastolic volume index, mass index, ejection fraction, GLS, LGE, Native T1,
233 ECV) were tested in the Cox models. Covariates with a p-value <0.05 in univariable analyses
234 were entered into the multivariable Cox model to identify independently prognostic variables,
235 using forward stepwise selection. Event-free survival curves were examined using the
236 Kaplan-Meier method and compared with the log-rank test. Statistical analyses were
237 performed using SPSS Version 28 (Statistical Package for the Social Sciences, International
238 Business Machines, Inc., Armonk, New York, USA) and GraphPad Prism 9.4.1 (GraphPad

239 Software, Inc., San Diego, California, USA). A two-sided p-value <0.05 was considered as
240 statistically significant.

241

242 **Results**

243 Figure 1 shows a flow chart describing patient inclusion. Of the 623 patients enrolled in the
244 ATTRaCT study, 523 patients underwent a baseline CMR study. We excluded 168 studies
245 performed without contrast. An additional 40 patients were excluded due to incomplete
246 baseline clinical or CMR data sets, alternative diagnosis on the basis of CMR, or loss to
247 follow-up. In total, 315 subjects (diabetes, n=159; without diabetes, n= 156) were included in
248 the study cohort.

249

250 The baseline clinical characteristics are shown in Table 1. Compared to patients without
251 diabetes, patients with diabetes were older (60 ± 10 vs 56 ± 12 years, $p<0.001$), more likely to
252 have a history of hypertension (76 vs 52%, $p<0.001$), coronary artery disease (72 vs 52%,
253 $p<0.001$) and had worse NYHA Functional Class (median Class II vs I, $p=0.04$). Patients
254 with diabetes had higher creatinine ($96 [81-118]$ vs $91 [77-105]$ $\mu\text{mol/L}$, $p=0.02$) and
255 elevated cardiac biomarkers: NT-proBNP ($1091 [326-2272]$ vs $579 [232-1136]$ pg/mL ,
256 $p<0.001$), hs-TnT ($27 [14-41]$ versus $15 [9-22]$ ng/L , $p<0.001$), GDF-15 ($2412 [1603-3331]$
257 versus $1039 [753-1470]$ pg/mL , $p<0.001$), sST2 ($28 [23-38]$ versus $26 [21-32]$ ng/mL ,
258 $p=0.038$) and Gal-3 ($10.0 [8.0-12.0]$ versus $8.0 [7.0-10.0]$ ng/mL , $p<0.001$). There was no
259 difference in LV ejection fraction and GLS between the groups. The diabetes group had a
260 higher prevalence of LGE (76 vs 60%, $p=0.002$, driven by higher rates of ischaemic LGE (51
261 vs 33%, $p=0.003$). Prevalence of non-ischaemic LGE did not differ between the groups. The
262 diabetes group had higher native T1 (1285 ± 42 vs 1269 ± 42 ms, $p<0.001$) and ECV (30.5 ± 3.5
263 vs $28.8\pm 4.1\%$, $p<0.001$). After adjustment for potential confounders, including age, sex,

264 hypertension and coronary artery disease, diabetes remained independently associated with
265 the presence of LGE and increased ECV ($p < 0.005$ for both analyses).

266

267 **Predictors of Primary Outcome in All Patients with Heart Failure**

268 Over a median follow-up of 23 [18-24] months, 74 patients experienced the primary outcome
269 (52 hospitalisations for HF, 22 all-cause deaths). In univariable Cox regression analyses for
270 the entire cohort, clinical markers associated with the primary outcome included diabetes,
271 NYHA functional class and systolic blood pressure. Circulating biomarkers associated with
272 the primary outcome included NT-proBNP, hs-TnT, GDF-15, sST2 and Gal-3. CMR markers
273 of adverse remodelling (LV mass index and end diastolic volume index), contractile function
274 (LV ejection fraction and GLS) and myocardial fibrosis (presence of LGE, native T1 and
275 ECV) were predictors of worse outcomes. Diabetes, NT-proBNP and GLS remained
276 independently associated with outcomes in the multivariable analysis (Table 2 and Figure 2).

277

278 **Predictors of Primary Outcome in Patients with Heart Failure and Diabetes**

279 In the diabetes group, 50 patients experienced the primary outcome (35 hospitalisations for
280 HF, 15 all-cause deaths). In univariable analyses, systolic blood pressure, NT-proBNP, hs-
281 TnT, GDF-15, sST2, LV ejection fraction, GLS and native T1 were associated with the
282 primary outcome (Table 3). GLS and sST2 remained associated with outcomes in the
283 multivariable analysis. Patients with diabetes and worse than median GLS ($GLS > -9.9\%$)
284 had the worst prognosis (log-rank $p < 0.001$, Figure 3). Of note, patients with diabetes and
285 GLS better than median had similar outcomes to patients without diabetes and GLS worse
286 than median (Figure 2B; $p = 0.70$).

287

288 In a multivariable model including clinical markers and plasma biomarkers, only sST2
289 remained independently associated with the primary outcome, demonstrating stronger
290 prognostic associations than NT-proBNP (Table 4).

291

292 The diabetes group was also stratified into four groups based on GLS (above or below
293 diabetes group median of -9.7%) and plasma biomarker (above or below median for NT-
294 proBNP, hs-TnT, GDF-15, sST2 and Gal-3). Amongst patients with above median GLS, NT-
295 proBNP and GDF-15 showed additional prognostic value (Supplemental Figure 1). On the
296 other hand, the combination of below median GLS and sST2 demonstrated particularly
297 adverse prognosis (Supplemental Figure 2).

298

299 **Discussion**

300 The main finding of this study is that GLS is a powerful independent predictor of adverse
301 outcomes in patients with HF and diabetes, providing incremental prognostic information
302 beyond several circulating plasma biomarkers and CMR markers of cardiac remodelling,
303 inflammation and fibrosis. In the diabetes group, worse GLS ($>$ median -9.9%) was
304 associated with adverse prognosis. GLS is known to have prognostic value in HF, regardless
305 of whether the cause is ischemic or non-ischemic and whether the EF is reduced or preserved
306 [14, 15]. In this study, we have extended those findings to the diabetes subgroup, who are
307 known to have a higher risk of adverse cardiovascular outcomes. Our findings are in
308 agreement with a prior study which showed that speckle tracking echocardiography (STE)
309 GLS has prognostic value in diabetes patients with dilated cardiomyopathy [28]. The results
310 from the current study raise the possibility of GLS-guided risk stratification and management
311 in patients with HF and diabetes. Indeed, there is emerging evidence of improvement in GLS
312 with anti-diabetic medications which may enable this in future [28-30].

313

314 GLS by CMR is well-suited for routine clinical use. The technique relies on software
315 packages which track the endocardial and epicardial borders, and reference values are
316 specific for the software used for analysis. STE has a number of limitations, including
317 dependence on high quality 2D images, and results are often affected by foreshortening,
318 dropout of the apical and anterolateral segments on apical views, and/or suboptimal acoustic
319 windows [15, 31, 32]. GLS by CMR overcomes these limitations and can be measured from
320 routinely acquired bright-blood, steady-state free precession long-axis cine imaging.
321 Disadvantages of GLS by CMR include its susceptibility to through-plane motion artefacts,
322 limited temporal resolution for quantification of strain rate, and limitations in patients with
323 contraindications to CMR [15]. Furthermore, GLS by CMR values may be affected by inter-
324 vendor differences in algorithms, similar to STE, which has resulted in difficulties
325 establishing reference values [32]. Nonetheless, GLS has shown close correlation with STE
326 and has become an important component of the CMR examination alongside volumetric
327 analysis and tissue characterisation in the assessment of HF [33].

328

329 In this study, sST2 demonstrated incremental prognostic value over other biomarkers
330 including NT-proBNP and hs-TnT in HF patients with diabetes. sST2 is produced by
331 cardiomyocytes and cardiac fibroblasts in response to myocardial stress, inflammation or
332 injury [34-36]. Other sources of sST2 include endothelial cells of the aorta and coronary
333 arteries as well as certain immune cells [34]. It acts as a decoy receptor for interleukin-33,
334 attenuating its cardioprotective biological effects which include blunting myocardial
335 hypertrophy and fibrosis, and inhibiting cardiomyocyte apoptosis [18, 34, 37]. We have
336 confirmed that sST2 levels are higher in HF patients with diabetes [38, 39]. Furthermore,
337 sST2 has known prognostic value in acute and chronic HF, independent of plasma natriuretic

338 peptides [40-42]. We have extended these findings to the subgroup of HF patients with
339 diabetes. This result provides further strength to the possibility that the prognostic value of
340 sST2 in heart failure may result from its association with metabolic perturbances that are also
341 commonly found in diabetes [43]. Our findings therefore suggest a possible role for sST2 in
342 risk stratification amongst HF patients with diabetes and in monitoring response to treatment
343 [44-49].

344

345 Diabetes was a strong independent predictor of the composite outcome of hospitalisation for
346 HF or all-cause mortality in this HF cohort. This is in agreement with prior studies which
347 have consistently shown worse cardiovascular outcomes in HF patients with diabetes,
348 regardless of HF etiology and whether the ejection fraction is reduced or preserved [8, 50,
349 51]. Furthermore, Kaplan-Meier survival analysis showed similar event rates in the diabetes
350 group with above median GLS ($\leq -9.9\%$) compared to those without diabetes and below
351 median GLS. These findings are similar to data from the Candesartan in Heart failure:
352 Assessment of Reduction in Mortality and morbidity (CHARM) study, which demonstrated
353 that patients with HF, preserved ejection fraction ($EF > 40\%$), and diabetes had a greater rate
354 of HF hospitalisation than those with lower ejection fraction ($EF \leq 40\%$) and no diabetes [8].
355 These findings highlight the urgent need for therapeutic advances in patients with HF and
356 concomitant diabetes.

357

358 In this study, HF patients with diabetes had worse CMR markers of myocardial injury,
359 inflammation, and fibrosis. The association between diabetes and elevated ECV remained
360 after adjusting for potential confounders that differed between the diabetic and non-diabetic
361 groups including age, hypertension, coronary artery disease and presence of LGE.
362 Furthermore, diabetes remained associated with the presence of LGE in logistic regression

363 models, even accounting for age, sex, hypertension and coronary artery disease. These
364 findings are in agreement with prior studies, including a recent meta-analysis, which showed
365 an association between diabetes and a higher degree of myocardial fibrosis as assessed by
366 histology as well as ECV by CMR [11].

367

368 Both focal and diffuse myocardial fibrotic processes are known to occur in patients with
369 diabetes independently of co-morbid conditions, including coronary atherosclerosis and
370 hypertension. Diffuse interstitial and perivascular fibrosis are structural hallmarks of diabetic
371 cardiomyopathy, but focal replacement fibrosis can also be seen, even in the absence of
372 coronary artery disease [52]. Several mechanisms may explain the fibrosis burden in diabetes.
373 Hyperglycaemia is thought to upregulate the expression of profibrotic factors such as
374 transforming growth factor beta 1 and down-regulate the activity of the matrix
375 metalloproteinases [53]. Hyperglycaemia is also known to promote the formation of
376 advanced glycation end products (AGEs) which can cross-link collagen in the interstitium,
377 increasing their resistance to degradation. AGEs can result in generation of reactive oxygen
378 species and oxidative stress which further promotes a pro-fibrotic state [11]. Pro-
379 inflammatory cytokines and chemokines, as well as increased renin-angiotensin-aldosterone
380 system activity in diabetes have also been implicated in the development of myocardial
381 fibrosis.

382

383 Native T1 values were higher in the diabetes group and may reflect interstitial expansion due
384 to myocardial fibrosis as well as myocardial oedema affecting the cellular and interstitial
385 compartments [54]. There is some disagreement in the literature regarding whether native T1
386 values are increased in diabetes. Several studies have shown an association between diabetes
387 and increased T1 [55-58]. Although a positive association was found between diabetes and

388 native T1 in a recent meta-analysis, the result was not statistically significant [11]. The
389 authors of that study suggested that the lack of statistical significance may have resulted from
390 limited sample size of the included studies. Indeed, the diabetes cohort in the present study
391 was larger than any of those in the included studies. Furthermore, T1 values are known to be
392 dependent on a variety of factors, including field strength, pulse sequence, and region of
393 measurement within the myocardium. In the present study, T1 maps were obtained at 3T
394 using the same MOLLI sequence for all patients, and with experienced observers performing
395 standardized analyses that may improve reproducibility and eliminate technical cofounders
396 [59, 60]. Whilst it does appear that diabetes is associated with higher T1, larger studies
397 controlling for the variability in T1 are required to more conclusively answer this question.

398

399 *Limitations*

400

401 One limitation of this study is the absence of measures of glycaemic control, which are
402 known to be prognostic in patients with HF and diabetes [61]. However, STE GLS is known
403 to have prognostic value independent of glycaemic control in diabetes cohorts with preserved
404 and reduced ejection fraction, and therefore this is unlikely to have altered the prognostic
405 associations for GLS by CMR [16, 28]. Our HF cohort included patients with both ischaemic
406 and non-ischaemic etiologies, as well as both preserved and reduced ejection fraction.
407 Unfortunately, the study was not powered for analyses of these subgroups. Documented
408 history of coronary artery disease did not associate with outcomes in the univariable analysis
409 and therefore etiology of HF is unlikely to have affected the results. Finally, this was a single
410 centre study using feature tracking software from a single vendor, limiting generalizability of
411 the results.

412

413 **Conclusions**

414 Patients with HF and diabetes had worse CMR and plasma markers of injury, inflammation,
415 and fibrosis, and an adverse prognosis. sST2 showed incremental prognostic value beyond
416 NT-proBNP in HF patients with diabetes. GLS is an important and independent prognostic
417 marker in this group. Future studies should explore whether GLS-guided risk stratification
418 and management can improve outcomes in this group of patients.

419

420 **Abbreviations**

421 HF: heart failure, GLS: global longitudinal strain, CMR: cardiovascular magnetic resonance, LGE: late
422 gadolinium enhancement, ECV: extracellular volume; NT-proBNP: N-terminal pro B-type natriuretic peptide,
423 hs-TnT: high-sensitivity troponin T, GDF-15: growth differentiation factor 15, sST2: soluble ST2, Gal-3:
424 galectin 3, left ventricle: LV.

425

426 **Declarations**

427 **Ethics approval and consent to participate**

428 Ethics approval was obtained from the local Centralized Institutional Review Board in Singapore, and all
429 participants provided written informed consent. The study was conducted in accordance with the principles of
430 the Declaration of Helsinki.

431

432 **Consent for publication**

433 Consent for the publication of images was given.

434

435 **Availability of data and materials**

436 The datasets generated and analysed for the current study are not publicly available. Please contact the
437 corresponding author for data requests.

438

439 **Competing interests**

440 CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore;
441 has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and
442 Vifor Pharma; has served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee
443 for Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim,
444 Boston Scientific, Corvia Medical, Cytokinetics, Darma Inc., Us2.ai, JanaCare, Janssen Research &
445 Development LLC, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group
446 Ltd., Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma and WebMD Global LLC;
447 and serves as co-founder & non-executive director of Us2.ai. MU is principal investigator for an institutional
448 research and development agreement regarding cardiovascular magnetic resonance imaging between Karolinska
449 University Hospital and Siemens. AMR receives research grants, consultancy fees, advisory board fees and/or
450 laboratory support-in-kind from Roche Diagnostics, Abbott Laboratories, Thermo Fisher, Novo Nordisk,
451 Sphingotec and Novartis and holds the New Zealand Heart Foundation Chair in Cardiovascular Studies. All
452 other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

453

454 **Funding**

455 The ATTRaCT study was supported by research grants from A*STAR Biomedical Research Council ATTRaCT
456 program [SPF2014/003, SPF2014/004, SPF2014/005] (A*STAR, Singapore). The funder had no role in study
457 design, data collection and analysis, decision to publish, or preparation of the manuscript.

458

459 **Authors' contributions**

460 CSPL and AMR designed the study. PJC, FE, RF and CWLC made substantial contributions to the study
461 design. NRI, SPC, OWL, JPCC, JAB and TTL collected the data. NRI analysed the data. NRI, MU and CWLC
462 interpreted the data and wrote the manuscript. CC and AMR made substantial revisions to the manuscript. All
463 authors read and approved the final manuscript.

464

465 **Acknowledgements**

466 The contribution of all the site investigators and clinical co-ordinators is acknowledged.

467

468

469

470 **References**

- 471 1. Lam CS, Teng TK, Tay WT, Anand I, Zhang S, Shimizu W, et al. Regional and
472 ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death
473 in heart failure registry. *Eur Heart J*. 2016;37(41):3141-53. Epub 2016/08/10. doi:
474 10.1093/eurheartj/ehw331. PubMed PMID: 27502121.
- 475 2. Ang N, Chandramouli C, Yiu K, Lawson C, Tromp J. Heart Failure and
476 Multimorbidity in Asia. *Curr Heart Fail Rep*. 2023;20(1):24-32. Epub 2023/02/23. doi:
477 10.1007/s11897-023-00585-2. PubMed PMID: 36811820; PubMed Central PMCID:
478 PMCPMC9977703.
- 479 3. Yap J, Tay WT, Teng TK, Anand I, Richards AM, Ling LH, et al. Association of
480 Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart
481 Failure With Reduced and Preserved Ejection Fraction. *J Am Heart Assoc*.
482 2019;8(17):e013114. Epub 2019/08/23. doi: 10.1161/JAHA.119.013114. PubMed PMID:
483 31431116; PubMed Central PMCID: PMCPMC6755825.
- 484 4. Connelly KA, Sarak B. Diabetes and Myocardial Fibrosis: Is CMR the Force Leading
485 to the Rise of "Scar Wars"? *JACC Cardiovasc Imaging*. 2022;15(5):809-11. Epub
486 2022/05/06. doi: 10.1016/j.jcmg.2022.01.015. PubMed PMID: 35512953.
- 487 5. Ritchie RH, Abel ED. Basic Mechanisms of Diabetic Heart Disease. *Circ Res*.
488 2020;126(11):1501-25. Epub 2020/05/22. doi: 10.1161/CIRCRESAHA.120.315913. PubMed
489 PMID: 32437308; PubMed Central PMCID: PMCPMC7251974.
- 490 6. Rosano GM, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus.
491 *Card Fail Rev*. 2017;3(1):52-5. Epub 2017/08/09. doi: 10.15420/cfr.2016:20:2. PubMed
492 PMID: 28785476; PubMed Central PMCID: PMCPMC5494155.
- 493 7. Johansson I, Dahlstrom U, Edner M, Nasman P, Ryden L, Norhammar A. Prognostic
494 Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure. *J Am*
495 *Coll Cardiol*. 2016;68(13):1404-16. Epub 2016/09/24. doi: 10.1016/j.jacc.2016.06.061.
496 PubMed PMID: 27659462.
- 497 8. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al.
498 Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart
499 failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality
500 and morbidity (CHARM) programme. *Eur Heart J*. 2008;29(11):1377-85. Epub 2008/04/17.
501 doi: 10.1093/eurheartj/ehn153. PubMed PMID: 18413309.
- 502 9. Chamsi-Pasha MA, Zhan Y, Debs D, Shah DJ. CMR in the Evaluation of Diastolic
503 Dysfunction and Phenotyping of HFpEF: Current Role and Future Perspectives. *JACC*
504 *Cardiovasc Imaging*. 2020;13(1 Pt 2):283-96. Epub 2019/06/17. doi:
505 10.1016/j.jcmg.2019.02.031. PubMed PMID: 31202753.
- 506 10. Kinno M, Nagpal P, Horgan S, Waller AH. Comparison of Echocardiography,
507 Cardiac Magnetic Resonance, and Computed Tomographic Imaging for the Evaluation of
508 Left Ventricular Myocardial Function: Part 1 (Global Assessment). *Curr Cardiol Rep*.
509 2017;19(1):9. Epub 2017/02/09. doi: 10.1007/s11886-017-0815-4. PubMed PMID:
510 28176279.
- 511 11. Salvador DB, Jr., Gamba MR, Gonzalez-Jaramillo N, Gonzalez-Jaramillo V,
512 Raguindin PFN, Minder B, et al. Diabetes and Myocardial Fibrosis: A Systematic Review
513 and Meta-Analysis. *JACC Cardiovasc Imaging*. 2022;15(5):796-808. Epub 2022/05/06. doi:
514 10.1016/j.jcmg.2021.12.008. PubMed PMID: 35512952.
- 515 12. Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of Underlying Mechanisms
516 for the Recognition and Management of Diabetic Cardiomyopathy. *J Am Coll Cardiol*.
517 2018;71(3):339-51. Epub 2018/01/20. doi: 10.1016/j.jacc.2017.11.019. PubMed PMID:
518 29348027.

- 519 13. Frojdh F, Fridman Y, Bering P, Sayeed A, Maanja M, Niklasson L, et al. Extracellular
520 Volume and Global Longitudinal Strain Both Associate With Outcomes But Correlate
521 Minimally. *JACC Cardiovasc Imaging*. 2020;13(11):2343-54. Epub 2020/06/22. doi:
522 10.1016/j.jcmg.2020.04.026. PubMed PMID: 32563637.
- 523 14. Romano S, Judd RM, Kim RJ, Kim HW, Klem I, Heitner JF, et al. Feature-Tracking
524 Global Longitudinal Strain Predicts Death in a Multicenter Population of Patients With
525 Ischemic and Nonischemic Dilated Cardiomyopathy Incremental to Ejection Fraction and
526 Late Gadolinium Enhancement. *JACC Cardiovasc Imaging*. 2018;11(10):1419-29. Epub
527 2018/01/24. doi: 10.1016/j.jcmg.2017.10.024. PubMed PMID: 29361479; PubMed Central
528 PMCID: PMC6043421.
- 529 15. Kammerlander AA, Dona C, Nitsche C, Koschutnik M, Schonbauer R, Duca F, et al.
530 Feature Tracking of Global Longitudinal Strain by Using Cardiovascular MRI Improves Risk
531 Stratification in Heart Failure with Preserved Ejection Fraction. *Radiology*. 2020;296(2):290-
532 8. Epub 2020/06/03. doi: 10.1148/radiol.2020200195. PubMed PMID: 32484413.
- 533 16. Holland DJ, Marwick TH, Haluska BA, Leano R, Hordern MD, Hare JL, et al.
534 Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus. *Heart*.
535 2015;101(13):1061-6. Epub 2015/05/04. doi: 10.1136/heartjnl-2014-307391. PubMed PMID:
536 25935767.
- 537 17. Wang Y, Yang H, Huynh Q, Nolan M, Negishi K, Marwick TH. Diagnosis of
538 Nonischemic Stage B Heart Failure in Type 2 Diabetes Mellitus: Optimal Parameters for
539 Prediction of Heart Failure. *JACC Cardiovasc Imaging*. 2018;11(10):1390-400. Epub
540 2018/05/21. doi: 10.1016/j.jcmg.2018.03.015. PubMed PMID: 29778859.
- 541 18. Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, et
542 al. Circulating heart failure biomarkers beyond natriuretic peptides: review from the
543 Biomarker Study Group of the Heart Failure Association (HFA), European Society of
544 Cardiology (ESC). *Eur J Heart Fail*. 2021;23(10):1610-32. Epub 2021/09/10. doi:
545 10.1002/ejhf.2346. PubMed PMID: 34498368; PubMed Central PMCID: PMC69292239.
- 546 19. Chan MM, Santhanakrishnan R, Chong JP, Chen Z, Tai BC, Liew OW, et al. Growth
547 differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. *Eur J*
548 *Heart Fail*. 2016;18(1):81-8. Epub 2015/10/27. doi: 10.1002/ejhf.431. PubMed PMID:
549 26497848.
- 550 20. Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupon J, Latini R, et al. sST2
551 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity
552 Troponin T. *J Am Coll Cardiol*. 2018;72(19):2309-20. Epub 2018/11/06. doi:
553 10.1016/j.jacc.2018.08.2165. PubMed PMID: 30384887.
- 554 21. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline
555 and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis
556 and effect of treatment with valsartan in the Val-HeFT. *Eur J Heart Fail*. 2013;15(5):511-8.
557 Epub 2013/01/08. doi: 10.1093/eurjhf/hfs205. PubMed PMID: 23291728.
- 558 22. Le TT, Tan RS, De Deyn M, Goh EP, Han Y, Leong BR, et al. Cardiovascular
559 magnetic resonance reference ranges for the heart and aorta in Chinese at 3T. *J Cardiovasc*
560 *Magn Reson*. 2016;18:21. Epub 2016/04/14. doi: 10.1186/s12968-016-0236-3. PubMed
561 PMID: 27071974; PubMed Central PMCID: PMC6043421.
- 562 23. Zhang S, Le TT, Kabus S, Su B, Hausenloy DJ, Cook SA, et al. Cardiac magnetic
563 resonance T1 and extracellular volume mapping with motion correction and co-registration
564 based on fast elastic image registration. *MAGMA*. 2018;31(1):115-29. Epub 2017/12/23. doi:
565 10.1007/s10334-017-0668-2. PubMed PMID: 29270904; PubMed Central PMCID:
566 PMC6043421.
- 567 24. Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG,
568 et al. Standardized image interpretation and post processing in cardiovascular magnetic

- 569 resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task
570 force on standardized post processing. *J Cardiovasc Magn Reson.* 2013;15(1):35. Epub
571 2013/05/03. doi: 10.1186/1532-429X-15-35. PubMed PMID: 23634753; PubMed Central
572 PMCID: PMCPMC3695769.
- 573 25. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, et al. Extracellular
574 volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical
575 myocardial pathology. *Eur Heart J.* 2012;33(10):1268-78. Epub 2012/01/27. doi:
576 10.1093/eurheartj/ehr481. PubMed PMID: 22279111; PubMed Central PMCID:
577 PMCPMC3350985.
- 578 26. Arheden H, Saeed M, Higgins CB, Gao DW, Bremerich J, Wyttenbach R, et al.
579 Measurement of the distribution volume of gadopentetate dimeglumine at echo-planar MR
580 imaging to quantify myocardial infarction: comparison with ^{99m}Tc-DTPA autoradiography
581 in rats. *Radiology.* 1999;211(3):698-708. Epub 1999/06/03. doi:
582 10.1148/radiology.211.3.r99jn41698. PubMed PMID: 10352594.
- 583 27. Cai J, Bryant JA, Le TT, Su B, de Marvao A, O'Regan DP, et al. Fractal analysis of
584 left ventricular trabeculations is associated with impaired myocardial deformation in healthy
585 Chinese. *J Cardiovasc Magn Reson.* 2017;19(1):102. Epub 2017/12/16. doi: 10.1186/s12968-
586 017-0413-z. PubMed PMID: 29241460; PubMed Central PMCID: PMCPMC5729602.
- 587 28. Tanaka H, Tatsumi K, Matsuzoe H, Matsumoto K, Hirata KI. Impact of diabetes
588 mellitus on left ventricular longitudinal function of patients with non-ischemic dilated
589 cardiomyopathy. *Cardiovasc Diabetol.* 2020;19(1):84. Epub 2020/06/15. doi:
590 10.1186/s12933-020-01063-y. PubMed PMID: 32534593; PubMed Central PMCID:
591 PMCPMC7293795.
- 592 29. Gamaza-Chulian S, Diaz-Retamino E, Gonzalez-Teston F, Gaitero JC, Castillo MJ,
593 Alfaro R, et al. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left
594 ventricular remodelling and longitudinal strain: a prospective observational study. *BMC*
595 *Cardiovasc Disord.* 2021;21(1):456. Epub 2021/09/23. doi: 10.1186/s12872-021-02250-9.
596 PubMed PMID: 34548011; PubMed Central PMCID: PMCPMC8456580.
- 597 30. Tanaka H, Soga F, Tatsumi K, Mochizuki Y, Sano H, Toki H, et al. Positive effect of
598 dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients
599 with chronic heart failure. *Cardiovasc Diabetol.* 2020;19(1):6. Epub 2020/01/09. doi:
600 10.1186/s12933-019-0985-z. PubMed PMID: 31910853; PubMed Central PMCID:
601 PMCPMC6947966.
- 602 31. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction:
603 a systematic review and meta-analysis of global longitudinal strain and ejection fraction.
604 *Heart.* 2014;100(21):1673-80. Epub 2014/05/27. doi: 10.1136/heartjnl-2014-305538.
605 PubMed PMID: 24860005.
- 606 32. Taylor RJ, Moody WE, Umar F, Edwards NC, Taylor TJ, Stegemann B, et al.
607 Myocardial strain measurement with feature-tracking cardiovascular magnetic resonance:
608 normal values. *Eur Heart J Cardiovasc Imaging.* 2015;16(8):871-81. Epub 2015/02/26. doi:
609 10.1093/ehjci/jev006. PubMed PMID: 25711353.
- 610 33. Onishi T, Saha SK, Delgado-Montero A, Ludwig DR, Onishi T, Schelbert EB, et al.
611 Global longitudinal strain and global circumferential strain by speckle-tracking
612 echocardiography and feature-tracking cardiac magnetic resonance imaging: comparison with
613 left ventricular ejection fraction. *J Am Soc Echocardiogr.* 2015;28(5):587-96. Epub
614 2015/01/13. doi: 10.1016/j.echo.2014.11.018. PubMed PMID: 25577185.
- 615 34. Sciatti E, Merlo A, Scangiuzzi C, Limonta R, Gori M, D'Elia E, et al. Prognostic
616 Value of sST2 in Heart Failure. *J Clin Med.* 2023;12(12). Epub 2023/06/28. doi:
617 10.3390/jcm12123970. PubMed PMID: 37373664; PubMed Central PMCID:
618 PMCPMC10299183.

- 619 35. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus
620 Panel. *Am J Cardiol.* 2015;115(7 Suppl):3B-7B. Epub 2015/02/11. doi:
621 10.1016/j.amjcard.2015.01.034. PubMed PMID: 25665766.
- 622 36. Berezin AE, Berezin AA. Circulating Cardiac Biomarkers in Diabetes Mellitus: A
623 New Dawn for Risk Stratification-A Narrative Review. *Diabetes Ther.* 2020;11(6):1271-91.
624 Epub 2020/05/21. doi: 10.1007/s13300-020-00835-9. PubMed PMID: 32430864; PubMed
625 Central PMCID: PMCPMC7261294.
- 626 37. Aimo A, Januzzi JL, Jr., Bayes-Genis A, Vergaro G, Sciarrone P, Passino C, et al.
627 Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the
628 Week. *J Am Coll Cardiol.* 2019;74(17):2193-203. Epub 2019/10/28. doi:
629 10.1016/j.jacc.2019.08.1039. PubMed PMID: 31648713.
- 630 38. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity
631 ST2 for prediction of adverse outcomes in chronic heart failure. *Circ Heart Fail.*
632 2011;4(2):180-7. Epub 2010/12/24. doi: 10.1161/CIRCHEARTFAILURE.110.958223.
633 PubMed PMID: 21178018; PubMed Central PMCID: PMCPMC3163169.
- 634 39. AbouEzzeddine OF, McKie PM, Dunlay SM, Stevens SR, Felker GM, Borlaug BA,
635 et al. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. *J*
636 *Am Heart Assoc.* 2017;6(2). Epub 2017/02/20. doi: 10.1161/JAHA.116.004382. PubMed
637 PMID: 28214792; PubMed Central PMCID: PMCPMC5523750.
- 638 40. Demissei BG, Cotter G, Prescott MF, Felker GM, Filippatos G, Greenberg BH, et al.
639 A multimarker multi-time point-based risk stratification strategy in acute heart failure: results
640 from the RELAX-AHF trial. *Eur J Heart Fail.* 2017;19(8):1001-10. Epub 2017/01/31. doi:
641 10.1002/ejhf.749. PubMed PMID: 28133908.
- 642 41. Aimo A, Vergaro G, Passino C, Ripoli A, Ky B, Miller WL, et al. Prognostic Value of
643 Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. *JACC*
644 *Heart Fail.* 2017;5(4):280-6. Epub 2016/11/07. doi: 10.1016/j.jchf.2016.09.010. PubMed
645 PMID: 27816512.
- 646 42. Aimo A, Vergaro G, Ripoli A, Bayes-Genis A, Pascual Figal DA, de Boer RA, et al.
647 Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart
648 Failure. *JACC Heart Fail.* 2017;5(4):287-96. Epub 2017/02/13. doi:
649 10.1016/j.jchf.2016.12.016. PubMed PMID: 28189578.
- 650 43. Miller AM, Purves D, McConnachie A, Asquith DL, Batty GD, Burns H, et al.
651 Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new
652 inflammatory pathway of relevance to diabetes? *PLoS One.* 2012;7(10):e47830. Epub
653 2012/11/01. doi: 10.1371/journal.pone.0047830. PubMed PMID: 23112853; PubMed Central
654 PMCID: PMCPMC3480428.
- 655 44. Gurgozze MT, van Vark LC, Baart SJ, Kardys I, Akkerhuis KM, Manintveld OC, et al.
656 Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI,
657 Creatinine, and Prognosis in Acute Heart Failure. *Circ Heart Fail.* 2023;16(1):e009526. Epub
658 2022/11/22. doi: 10.1161/CIRCHEARTFAILURE.122.009526. PubMed PMID: 36408685;
659 PubMed Central PMCID: PMCPMC9833118.
- 660 45. van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, Orsel JG, et al.
661 Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. *J Am*
662 *Coll Cardiol.* 2017;70(19):2378-88. Epub 2017/11/04. doi: 10.1016/j.jacc.2017.09.026.
663 PubMed PMID: 29096809.
- 664 46. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al.
665 Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after
666 acute myocardial infarction. *J Am Coll Cardiol.* 2010;55(3):243-50. Epub 2010/02/02. doi:
667 10.1016/j.jacc.2009.08.047. PubMed PMID: 20117403.

- 668 47. Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi JL, Jr. Soluble
669 concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in
670 chronic heart failure. *Circ Heart Fail*. 2013;6(6):1206-13. Epub 2013/10/12. doi:
671 10.1161/CIRCHEARTFAILURE.113.000457. PubMed PMID: 24114865.
- 672 48. Maisel A, Xue Y, van Veldhuisen DJ, Voors AA, Jaarsma T, Pang PS, et al. Effect of
673 spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study).
674 *Am J Cardiol*. 2014;114(5):737-42. Epub 2014/08/19. doi: 10.1016/j.amjcard.2014.05.062.
675 PubMed PMID: 25129066.
- 676 49. Bayes-Genis A, Aimo A, Jhund P, Richards M, de Boer RA, Arfsten H, et al.
677 Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of
678 the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*.
679 2022;24(10):1767-77. Epub 2022/09/09. doi: 10.1002/ejhf.2675. PubMed PMID: 36073112.
- 680 50. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, et
681 al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST
682 trial. *J Am Coll Cardiol*. 2003;42(5):914-22. Epub 2003/09/06. doi: 10.1016/s0735-
683 1097(03)00856-8. PubMed PMID: 12957443.
- 684 51. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al. Diabetes
685 mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction
686 (SOLVD) Trials and Registry. *Am J Cardiol*. 1996;77(11):1017-20. Epub 1996/05/01. doi:
687 10.1016/s0002-9149(97)89163-1. PubMed PMID: 8644628.
- 688 52. Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: Cellular effectors,
689 molecular mechanisms and therapeutic opportunities. *J Mol Cell Cardiol*. 2016;90:84-93.
690 Epub 2015/12/26. doi: 10.1016/j.yjmcc.2015.12.011. PubMed PMID: 26705059; PubMed
691 Central PMCID: PMC4718740.
- 692 53. Borghetti G, von Lewinski D, Eaton DM, Sourij H, Houser SR, Wallner M. Diabetic
693 Cardiomyopathy: Current and Future Therapies. *Beyond Glycemic Control*. *Front Physiol*.
694 2018;9:1514. Epub 2018/11/15. doi: 10.3389/fphys.2018.01514. PubMed PMID: 30425649;
695 PubMed Central PMCID: PMC6218509.
- 696 54. Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1
697 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. *J*
698 *Cardiovasc Magn Reson*. 2016;18(1):89. Epub 2016/12/03. doi: 10.1186/s12968-016-0308-4.
699 PubMed PMID: 27899132; PubMed Central PMCID: PMC4718740.
- 700 55. Swoboda PP, McDiarmid AK, Erhayiem B, Ripley DP, Dobson LE, Garg P, et al.
701 Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and
702 Monitoring of Individuals at Risk of Heart Failure. *J Am Heart Assoc*. 2017;6(7). Epub
703 2017/07/19. doi: 10.1161/JAHA.117.005539. PubMed PMID: 28716801; PubMed Central
704 PMCID: PMC4718740.
- 705 56. Cao Y, Zeng W, Cui Y, Kong X, Wang M, Yu J, et al. Increased myocardial
706 extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its
707 determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain.
708 *Cardiovasc Diabetol*. 2018;17(1):7. Epub 2018/01/06. doi: 10.1186/s12933-017-0651-2.
709 PubMed PMID: 29301529; PubMed Central PMCID: PMC5755204.
- 710 57. Lam B, Stromp TA, Hui Z, Vandsburger M. Myocardial native-T1 times are elevated
711 as a function of hypertrophy, HbA1c, and heart rate in diabetic adults without diffuse fibrosis.
712 *Magn Reson Imaging*. 2019;61:83-9. Epub 2019/05/28. doi: 10.1016/j.mri.2019.05.029.
713 PubMed PMID: 31125612; PubMed Central PMCID: PMC663625.
- 714 58. Kucukseymen S, Neisius U, Rodriguez J, Tsao CW, Nezafat R. Negative synergism
715 of diabetes mellitus and obesity in patients with heart failure with preserved ejection fraction:
716 a cardiovascular magnetic resonance study. *Int J Cardiovasc Imaging*. 2020;36(10):2027-38.
717 Epub 2020/06/14. doi: 10.1007/s10554-020-01915-4. PubMed PMID: 32533279.

718 59. Kellman P, Hansen MS. T1-mapping in the heart: accuracy and precision. *J*
719 *Cardiovasc Magn Reson.* 2014;16(1):2. Epub 2014/01/07. doi: 10.1186/1532-429X-16-2.
720 PubMed PMID: 24387626; PubMed Central PMCID: PMC3927683.
721 60. Treibel TA, Fridman Y, Bering P, Sayeed A, Maanja M, Frojdh F, et al. Extracellular
722 Volume Associates With Outcomes More Strongly Than Native or Post-Contrast Myocardial
723 T1. *JACC Cardiovasc Imaging.* 2020;13(1 Pt 1):44-54. Epub 2019/05/20. doi:
724 10.1016/j.jcmg.2019.03.017. PubMed PMID: 31103587.
725 61. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C
726 and mortality in heart failure patients with diabetes. *J Am Coll Cardiol.* 2009;54(5):422-8.
727 Epub 2009/07/25. doi: 10.1016/j.jacc.2009.04.049. PubMed PMID: 19628117; PubMed
728 Central PMCID: PMC3927683.

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745 **Figure Titles and Legends**

746 **Figure 1. Flow chart of patient inclusion.** Abbreviations: HF: heart failure; ECG: 12-lead
747 electrocardiogram; CMR: Cardiovascular magnetic resonance; HCM: Hypertrophic
748 cardiomyopathy.

749 **Figure 2. Event-free survival curves showing:** (A) Adverse prognosis in patients with heart
750 failure and diabetes; (B) Patients with diabetes and GLS worse than cohort median (-9.9%) had
751 worst prognosis. Patients with either diabetes or GLS worse than median had similar outcomes.
752 Abbreviations: DM: diabetes mellitus; GLS: global longitudinal strain

753 **Figure 3. Example of GLS measurement in apical 2-chamber view. Top panel** shows a
754 patient with heart failure, diabetes and $GLS \leq -9.9\%$. **Bottom panel** shows a patient with heart
755 failure, diabetes and $GLS > -9.9\%$. **Centre panel:** event-free survival curves showing adverse
756 prognosis in patients with heart failure, diabetes and GLS worse than cohort median (-9.9%).
757 Abbreviations: DM: diabetes mellitus; GLS: global longitudinal strain.

758 **Supplemental Figures**

759 **Supplemental Figure 1. Event-free survival curves in patients with diabetes and above**
760 **median GLS (-9.7%) stratified by:** (A) NT-proBNP; (B) hs-TnT; (C) GDF-15; (D) sST2 and
761 (E) Gal-3. NT-proBNP and GDF-15 demonstrated additional prognostic value in this group.
762 Abbreviations: GLS: global longitudinal strain; NT-proBNP: N-terminal pro-brain natriuretic
763 peptide; hs-TnT: high-sensitivity troponin T; GDF-15: growth differentiation factor 15; sST2:
764 soluble ST2; Gal-3: galectin 3.

765 **Supplemental Figure 2. Event-free survival curves in patients with diabetes and below**
766 **median GLS (-9.7%) stratified by:** (A) NT-proBNP; (B) hs-TnT; (C) GDF-15; (D) sST2 and

767 (E) Gal-3. sST2 demonstrated additional prognostic value in this group. Abbreviations: GLS:
768 global longitudinal strain; NT-proBNP: N-terminal pro-brain natriuretic peptide; hs-TnT: high-
769 sensitivity troponin T; GDF-15: growth differentiation factor 15; sST2: soluble ST2; Gal-3:
770 galectin 3.

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785 Table 1. Baseline clinical characteristics of the cohort according to presence or absence of
786 diabetes.

	No Diabetes Mellitus (n=156)	Diabetes Mellitus (n=159)	p Value
Clinical			
Age, years	56 ± 12	60 ± 10	<0.001
Male sex, n (%)	129 (83)	126 (79)	0.436
Heart rate, beats/min	71 [63-81]	75 [68-83]	0.020
Systolic BP, mmHg	124 [111-138]	125 [113-143]	0.240
Diastolic BP, mmHg	73 [66-82]	70 [61-80]	0.008
Body mass index, kg/m ²	26 [23-30]	27 [23-31]	0.412
Co-morbidities, n (%)			
Hypertension	80 (52)	120 (76)	<0.001
Coronary artery disease	78 (52)	112 (72)	<0.001
Atrial Fibrillation	22 (14)	29 (18)	0.331
Medications at baseline, n (%)			
Beta Blocker	135 (87)	146 (92)	0.436
ACEi or ARB	129 (83)	140 (88)	0.178
Mineralocorticoid antagonist	98 (63)	102 (64)	0.806
Diuretic	116 (74)	129 (81)	0.148
Statin	120 (77)	146 (92)	<0.001
NYHA Functional Class, n (%)			0.041
Class I	91 (58)	75 (47)	
Class II	51 (33)	74 (47)	
Class III	14 (9)	10 (6)	
MLWHF Score	12 [0-30]	14 [3-29]	0.299
Haematocrit, (%)	43 ± 5	41 ± 6	<0.001
Creatinine, µmol/L	91 [77-105]	96 [81-118]	0.016
Plasma Biomarkers			

NT-proBNP, pg/mL	579 [232-1136]	1091 [326-2272]	<0.001
hs-TnT, ng/L	15 [9-22]	27 [14-41]	<0.001
GDF-15, pg/mL	1039 [753-1470]	2412 [1603-3331]	<0.001
sST2, ng/mL	26 [21-32]	28 [23-38]	0.038
Gal-3, ng/mL	8.0 [7.0-10.0]	10.0 [8.0-12.0]	<0.001
CMR Markers			
LVEDVi, mL/m ²	112 [83-142]	99 [81-129]	0.029
LVESVi, mL/m ²	71 [43-105]	65 [40-94]	0.190
SVi, mL/m ²	39 [32-44]	35 [29-42]	0.005
LVMi, g/m ²	70 [59-89]	67 [55-83]	0.125
LV ejection fraction, %	36 [25-49]	36 [26-49]	0.947
GLS, %	-10.1 ± 4.1	-9.8 ± 3.7	0.443
LAVi, mL/m ²	48 [38-68]	47 [33-65]	0.285
LGE Type			0.003
Nil, n (%)	63 (40)	38 (24)	
Non-ischaemic, n (%)	38 (24)	34 (21)	
Ischaemic, n (%)	52 (33)	81 (51)	
Both, n (%)	3 (2)	6 (4)	
Native T1, ms	1269 ± 42	1285 ± 42	<0.001
ECV, %	28.8 ± 4.1	30.5 ± 3.5	<0.001

787 Values are given as median [interquartile range], mean ± SD or number (percentage).
788 **Abbreviations**: ACEi: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor
789 blocker; NYHA: New York Heart Association; MLWHF: Minnesota Living with Heart Failure;
790 NT-proBNP: N-terminal pro-brain natriuretic peptide; hs-TnT: high-sensitivity troponin T; GDF-
791 15: growth differentiation factor 15; sST2: soluble ST2; Gal-3: galectin 3; LVEDVi: Left
792 ventricular end-diastolic volume indexed to body surface area; LVESVi: Left ventricular end-
793 systolic volume index; SVi: Stroke volume index; LVMi: Left ventricular mass index; GLS:
794 Global longitudinal strain; LAVi: Left atrial end-systolic volume index; LGE: Late gadolinium
795 enhancement; ECV: Extracellular volume.

796
797
798
799
800
801

802 Table 2. Univariable and multivariable Cox regression models (stepwise selection) in the
803 entire cohort for the primary outcome of all-cause mortality or heart failure hospitalisation.

	Univariable Model		Multivariable Model (n=314)	
	HR (95% CI)	P Value	HR (95% CI)	p Value
Clinical				
Age (per 10-year increment)	1.20 (0.97-1.47)	0.101		
Male sex	0.82 (0.44-1.53)	0.537		
Body mass index	0.97 (0.93-1.01)	0.137		
Smoking	1.17 (0.74-1.86)	0.503		
Hypertension	0.86 (0.54-1.37)	0.528		
Diabetes	2.33 (1.43-3.79)	<0.001	2.30 (1.41-3.74)	<0.001
Coronary artery disease	1.54 (0.94-2.53)	0.090		
NYHA Functional Class	1.61 (1.15-2.25)	0.006	§	
Systolic blood pressure (per 10mmHg increment)	0.88 (0.78-0.98)	0.020	§	
Plasma Biomarkers				
NT-proBNP (per 100pg/mL increment)	1.01 (1.01-1.02)	<0.001	1.01 (1.00-1.01)	0.02
hs-TnT (per 1ng/L increment)	1.01 (1.01-1.02)	<0.001	§	
GDF-15 (per 100pg/mL increment)	1.02 (1.01-1.03)	<0.001	§	
sST2 (per 1ng/mL increment)	1.02 (1.01-1.04)	0.004	§	
Gal-3 (per 1ng/mL increment)	1.09 (1.04-1.14)	<0.001	§	
CMR Markers				
LVEDVi (per 10mL/m ² increment)	1.07 (1.03-1.12)	<0.001	§	
LVMi (per 10g/m ² increment)	1.10 (1.01-1.22)	0.032	§	
LV ejection fraction (per 5% increment)	0.90 (0.83-1.00)	0.010	§	
GLS	1.16 (1.09-1.24)	<0.001	1.14 (1.06-1.22)	<0.001
Presence of LGE	1.94 (1.10-3.42)	0.022	§	
Native T1 (per 10ms increment)	1.09 (1.04-1.15)	<0.001	§	
ECV	1.06 (1.02-1.11)	0.005	§	

804 **Abbreviations**; NYHA: New York Heart Association; NT-proBNP: N-terminal pro-brain
 805 natriuretic peptide; hs-TnT: high-sensitivity troponin T; GDF-15: growth differentiation
 806 factor 15; sST2: soluble ST2; Gal-3: galectin 3; LVEDVi: Left ventricular end-diastolic
 807 volume indexed to body surface area; LVMI: Left ventricular mass index; GLS: Global
 808 longitudinal strain; LGE: Late gadolinium enhancement; ECV: Extracellular volume.
 809 § Assessed for inclusion in multivariable model but not retained.

810
 811

812 Table 3. Univariable and multivariable Cox regression models (stepwise selection) in the
 813 diabetes group for the primary outcome of all-cause mortality or heart failure
 814 hospitalisation.

	Univariable Model		Multivariable Model (n=158)	
	HR (95% CI)	P Value	HR (95% CI)	p Value
Clinical				
Age (per 10-year increment)	1.21 (0.90-1.60)	0.202		
Male sex	0.85 (0.41-1.75)	0.665		
Body mass index	0.99 (0.94-1.05)	0.827		
Hypertension	0.94 (0.50-1.76)	0.838		
Diabetes Type	0.88 (0.28-2.84)	0.836		
Smoking	0.80 (0.46-1.40)	0.436		
Coronary artery disease	1.41 (0.72-2.75)	0.314		
NYHA Functional Class	1.34 (0.86-2.08)	0.200		
Systolic blood pressure (per 10mmHg increment)	0.86 (0.75-0.98)	0.028	§	
Plasma Biomarkers				
NT-proBNP (per 100pg/mL increment)	1.01 (1.00-1.02)	0.007	§	
hs-TnT (per 1ng/L increment)	1.01 (1.00-1.02)	0.016	§	
GDF-15 (per 100pg/mL increment)	1.02 (1.01-1.03)	0.003	§	
sST2 (per 1ng/mL increment)	1.03 (1.01-1.06)	0.003	1.03 (1.00-1.06)	0.02
Gal-3 (per 1ng/mL increment)	1.06 (1.00-1.12)	0.061		
CMR Markers				
LVEDVi (per 10mL/m ² increment)	1.07 (0.99-1.15)	0.076		
LVMI (per 10g/m ² increment)	1.01 (0.88-1.15)	0.928		

LV ejection fraction (per 5% increment)	0.89 (0.81-0.99)	0.031	§	
GLS	1.15 (1.06-1.25)	0.001	1.12 (1.03-1.21)	0.01
Presence of LGE	1.42 (0.69-2.92)	0.342		
Native T1 (per 10ms increment)	1.07 (1.00-1.14)	0.04	§	
ECV	1.06 (0.98-1.15)	0.139		

815 **Abbreviations:**; NYHA: New York Heart Association; NT-proBNP: N-terminal pro-brain
816 natriuretic peptide; hs-TnT: high-sensitivity troponin T; GDF-15: growth differentiation
817 factor 15; sST2: soluble ST2; Gal-3: galectin 3; LVEDVi: Left ventricular end-diastolic
818 volume indexed to body surface area; LVMI: Left ventricular mass index; GLS: Global
819 longitudinal strain; LGE: Late gadolinium enhancement; ECV: Extracellular volume.
820 § Assessed for inclusion in multivariable model but not retained.

821

822

823 Table 4. Multivariable Cox regression model (Clinical and Plasma biomarkers) in the diabetes

824 group for the primary outcome of all-cause mortality or heart failure hospitalisation.

	Multivariable Model (n=158)	
	HR (95% CI)	p Value
Clinical		
Age (per 10-year increment)		
Male sex		
Body mass index		
Hypertension		
Diabetes Type		
Smoking		
Coronary artery disease		
NYHA Functional Class		
Systolic blood pressure (per 10mmHg increment)	§	
Plasma Biomarkers		
NT-proBNP (per 100pg/mL increment)	§	
high-sensitivity troponin T	§	
GDF-15 (per 100pg/mL increment)	§	
sST2	1.04 (1.02-1.07)	0.001


Gal-3


825 **Abbreviations:**; NYHA: New York Heart Association; NT-proBNP: N-terminal pro-brain
826 natriuretic peptide; hs-TnT: high-sensitivity troponin T; GDF-15: growth differentiation
827 factor 15; sST2: soluble ST2; Gal-3: galectin 3.

828 § Assessed for inclusion in multivariable model but not retained.


829

830





	0	6	12	18	24
DM-	156	147	142	132	76
DM+	159	139	125	105	49



	0	6	12	18	24
DM-, GLS \leq -9.9%	81	78	77	74	41
DM+, GLS \leq -9.9%	78	70	67	58	30
DM-, GLS $>$ -9.9%	75	69	65	58	35
DM+, GLS $>$ -9.9%	81	69	58	47	19

